Secondary outcomes by prior definitive treatment (tx) in patients (pts) with high-risk biochemically recurrent prostate cancer (hrBCR) treated with enzalutamide (enza) monotherapy (mono): EMBARK post hoc analysis.

Detalles Bibliográficos
Publicado en:	Journal of Clinical Oncology Vol. 43; pp. 179 - 467
Autores principales:	Freedland, Stephen J., De Giorgi, Ugo, Tutrone, Ronald F., Karsh, Lawrence Ivan, Ramirez-Backhaus, Miguel, Uchio, Edward M., Tang, Yiyun, Croitoru, Ruslan, Rosales, Matt, Kalac, Matko, Wang, Fong, Shore, Neal D.
Formato:	Journal Article
Publicado:	American Society of Clinical Oncology 2/20/2025 Supplement 5
Acceso en línea:	Ver este registro en EBSCOhost